Comparative Pharmacology
Head-to-head clinical analysis: KEFLIN IN PLASTIC CONTAINER versus OMNICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFLIN IN PLASTIC CONTAINER versus OMNICEF.
KEFLIN IN PLASTIC CONTAINER vs OMNICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalothin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity, leading to cell lysis and death.
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1 to 2 g IV or IM every 4 to 6 hours. Maximum 12 g/day.
300 mg orally twice daily for 10 days; or 600 mg orally once daily for 10 days (for community-acquired pneumonia, acute exacerbations of chronic bronchitis, sinusitis, pharyngitis/tonsillitis, uncomplicated skin infections).
None Documented
None Documented
0.5-1 hour in normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <10 mL/min)
1.7 hours (range 1.2–2.3 h) in healthy adults; prolonged to 3.2–6.6 h in renal impairment (CrCl <30 mL/min); no significant change in hepatic impairment.
Renal: 60-80% unchanged; biliary/fecal: minimal (<1%)
Renal excretion as unchanged drug: 80-90% (primarily via glomerular filtration and tubular secretion); biliary/fecal: 10-20% (minor).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic